Filter Results:
(999)
Show Results For
- All HBS Web
(999)
- People (4)
- News (260)
- Research (614)
- Events (9)
- Multimedia (24)
- Faculty Publications (397)
Show Results For
- All HBS Web
(999)
- People (4)
- News (260)
- Research (614)
- Events (9)
- Multimedia (24)
- Faculty Publications (397)
- November 2018
- Case
David Hysong and SHEPHERD Therapeutics
By: Ananth Raman, John Masko and Aldo Sesia
In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his... View Details
- March 2007
- Teaching Note
Amgen Inc.'s Epogen-Commercializing the First Biotech Blockbuster Drug (TN)
Teaching note to 706454. View Details
- 2004
- Book
Pharmacopolitics: Drug Regulation in the United States and Germany
By: Arthur A. Daemmrich
Keywords: Health; Governing Rules, Regulations, and Reforms; Government and Politics; United States; Germany
Daemmrich, Arthur A. Pharmacopolitics: Drug Regulation in the United States and Germany. University of North Carolina Press, 2004. (Winner of Edward Kremers Award of the American Institute of the History of Pharmacy For best book in pharmaco-historical writing published in the previous two years presented by American Institute of the History of Pharmacy.)
- September 2001 (Revised October 2001)
- Teaching Note
Merck & Company: Evaluating A Drug Licensing Opportunity TN
By: Richard S. Ruback and Aldo Sesia
Teaching Note for (9-201-023). View Details
Keywords: Service Industry
- September 1996
- Case
Food and Drug Administration: Business as Unusual at CDER
By: Steven C. Wheelwright and James Leonard
Wheelwright, Steven C., and James Leonard. "Food and Drug Administration: Business as Unusual at CDER." Harvard Business School Case 697-022, September 1996.
- 01 Mar 2004
- News
Drug Imports a Hot Topic at Alumni Health-Care Conference
FDA Commissioner Mark B. McClellan doesn’t approve of Americans buying low-cost prescription drugs from Canada or over the Internet. But he understands what drives them to do so. At the HBS Health Industry Alumni Association’s fourth... View Details
- Article
Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users
By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details
Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States
Stern, Ariel Dora, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup, and Ernst R. Berndt. "Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users." Health Affairs 40, no. 6 (June 2021): 989–999.
- 1996
- Chapter
The Determinants of Research Productivity in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
- Fast Answer
Pharmaceuticals: drug approval dates in the UK and Europe
Where can I find drug approval dates for the UK? The European Medicines Agency provides information on drug approvals in the UK and Europe: EMA Annual Reports and Work Programmes provides list of new... View Details
- 03 Apr 2015
- News
The Apple Watch: A gateway drug for Swiss horology
- November 1969 (Revised February 1973)
- Background Note
Note on the U.S. Prescription Drug Industry, Part II
By: Hugo Uyterhoeven and Audrey T. Sproat
Uyterhoeven, Hugo, and Audrey T. Sproat. "Note on the U.S. Prescription Drug Industry, Part II." Harvard Business School Background Note 370-039, November 1969. (Revised February 1973.)
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of... View Details
Keywords: Cost vs Benefits; Decisions; Judgments; Values and Beliefs; Global Strategy; Health Care and Treatment; Patents; Growth and Development Strategy; Growth Management; Product Positioning; Supply and Industry; Supply Chain; Corporate Social Responsibility and Impact; Mission and Purpose; Philanthropy and Charitable Giving; Opportunities; Social Issues; Equality and Inequality; Pharmaceutical Industry; Health Industry; Denmark; United States; Europe; China; India; Middle East; North Africa
Badaracco, Joseph L., Tom Quinn, and John Schultz. "Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs." Harvard Business School Case 324-114, April 2024. (Revised July 2024.)
- 17 Jul 2013
- News
For Global Drug Manufacturers, China Becomes a Perilous Market
- September 2022
- Article
Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities
By: Leemore Dafny, Christopher Ody and Teresa Rokos
The federal Anti-Kickback Statute prohibits biopharmaceutical manufacturers from directly covering Medicare enrollees’ out-of-pocket spending for the drugs they manufacture, but manufacturers may donate to independent patient assistance charities and earmark donations... View Details
Keywords: Cost Sharing; Prescription Drugs; Drug Spending; Medicare; Dual Eligibility; Cost; Health Care and Treatment; Philanthropy and Charitable Giving; Pharmaceutical Industry
Dafny, Leemore, Christopher Ody, and Teresa Rokos. "Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities." Health Affairs 41, no. 9 (September 2022).
- March 2011
- Teaching Note
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration (TN)
By: Karim R. Lakhani
Teaching Note for 610074. View Details
- 2008
- Case
Eli Lilly: Recreating Drug Discovery for the 21st Century
By: Rebecca Henderson and C. Reavis
- 19 Jul 2019
- News
Can Germany help the U.S. lower prescription drug prices?
- 2018
- Chapter
The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century
By: Nicholas Bagley, Benjamin Berger, Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
On the 35th anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormous changes in the markets for therapies for rare diseases that have emerged over recent decades. The most prominent example is the fact that the profit-maximizing price of new... View Details
Keywords: Health Care and Treatment; Laws and Statutes; Research and Development; Investment; Markets; Monopoly
Bagley, Nicholas, Benjamin Berger, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern. "The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century." Chap. 4 in Innovation Policy and the Economy, Volume 19, edited by Josh Lerner and Scott Stern, 97–137. University of Chicago Press, 2018.